Cutting edge: Fas ligand (CD178) cytoplasmic tail is a positive regulator of Fas ligand-mediated

被引:10
|
作者
Jodo, S
Pidiyar, VJ
Xiao, S
Furusaki, A
Sharma, R
Koike, T
Ju, ST [1 ]
机构
[1] Univ Virginia, Dept Internal Med, Div Rheumatol & Immunol, Charlottesville, VA 22908 USA
[2] Hokkaido Univ, Grad Sch Med, Dept Med 2, Sapporo, Hokkaido, Japan
来源
JOURNAL OF IMMUNOLOGY | 2005年 / 174卷 / 08期
关键词
D O I
10.4049/jimmunol.174.8.4470
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The cytotoxic function of CD178 (Tas ligand (FasL)) is critical to the maintenance of peripheral tolerance and immune-mediated tissue pathology. The active site of FasL resides at the FasL extracellular region (FasL(Ext)) and it functions through binding/cross-linking Fas receptor on target cells. In this study, we report that FasL(Ext)-mediated cytotoxicity is regulated by the FasL cytoplasmic tail (Fas(LCyt)). Deleting the N-terminal 2-70 aa (Delta 70) or N-terminal 2-33 aa (Delta 33) reduced the cytotoxic strength as much as 30- to 100-fold. By contrast, change in the cytotoxic strength was not observed with FasL deleted of the proline-rich domains (45-74 aa, Delta PRD) in the FasL(Cyt) Our study identifies a no velfunction of FasL(Cyt) and demonstrates that FasL(Cyt), a sequence unique to FasL, is critically required for the optimal expression of FasL(Ext)-mediated cytotoxicity.
引用
收藏
页码:4470 / 4474
页数:5
相关论文
共 50 条
  • [31] Evidence for UV-induced autocrine Fas/Fas ligand-mediated keratinocyte apoptosis.
    Leverkus, M
    Yaar, M
    Gilchrest, BA
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 106 (04) : 132 - 132
  • [32] Regulation of fas/fas ligand-mediated apoptosis by nuclear factor of activated T cells in megakaryocytes
    Arabanian, Laleh S.
    Kujawski, Satu
    Habermann, Ivonne
    Ehninger, Gerhard
    Kiani, Alexander
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (04) : 523 - 534
  • [33] Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus
    Suzuki, N
    Ichino, M
    Mihara, S
    Kaneko, S
    Sakane, T
    ARTHRITIS AND RHEUMATISM, 1998, 41 (02): : 344 - 353
  • [34] Fas-Fas Ligand-mediated apoptosis within aqueous during idiopathic acute anterior uveitis
    Dick, AD
    Siepmann, K
    Dees, C
    Duncan, L
    Broderick, C
    Liversidge, J
    Forrester, JV
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1999, 40 (10) : 2258 - 2267
  • [35] Fas/Fas Ligand-mediated Apoptosis in Different Cell Lineages and Functional Compartments of Human Lymph Nodes
    Kokkonen, Tuomo S.
    Karttunen, Tuomo J.
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2010, 58 (02) : 131 - 140
  • [36] S-Nitrosylation of the Death Receptor Fas Promotes Fas Ligand-Mediated Apoptosis in Cancer Cells
    Leon-Bollotte, Lissbeth
    Subramaniam, Selvakumar
    Cauvard, Olivier
    Plenchette-Colas, Stephanie
    Paul, Catherine
    Godard, Cindy
    Martinez-Ruiz, Antonio
    Legembre, Patrick
    Jeannin, Jean-Francois
    Bettaieb, Ali
    GASTROENTEROLOGY, 2011, 140 (07) : 2009 - U242
  • [37] Fas/Fas ligand-mediated elimination of antigen-bearing Langerhans cells in draining lymph nodes
    Kawamura, T
    Azuma, M
    Kayagaki, N
    Shimada, S
    Yagita, H
    Okumura, K
    BRITISH JOURNAL OF DERMATOLOGY, 1999, 141 (02) : 201 - 205
  • [38] Fas/Fas Ligand-mediated Apoptosis Promotes Hypersensitivity Pneumonitis in Mice by Enhancing Maturation of Dendritic Cells
    Hwang, Su Jin
    Kim, Hye Sung
    Chung, Doo Hyun
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181 (11) : 1250 - 1261
  • [39] Fas/Fas ligand-mediated elimination of cytotoxic CD8+lymphocyte in mycosis fungoides: A potential mechanism of tumor immune escape?
    Ni, X
    Hazarika, P
    Zhang, C
    Duvic, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (02) : 490 - 490
  • [40] Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+T cell count after antiretroviral therapy in drug-naive HIV-positive patients
    Nasi, M
    Pinti, M
    Bugarini, R
    Troiano, L
    Lugli, E
    Bellodi, C
    Mussini, C
    Borghi, V
    Trenti, T
    Balli, F
    Esposito, R
    Cossarizza, A
    IMMUNOGENETICS, 2005, 57 (09) : 628 - 635